• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阵发性心房颤动:深入了解凝血的内在机制

Paroxysmal Atrial Fibrillation: Insight Into the Intimate Mechanisms of Coagulation.

作者信息

Negreva Mariya, Zarkova Ana, Prodanova Krasimira, Petrov Petar

机构信息

Department of Cardiology, Medical University of Varna, Varna, Bulgaria.

National Specialized Hospital for Active Treatment of Hematologic Diseases, Sofia, Bulgaria.

出版信息

Cardiol Res. 2020 Feb;11(1):22-32. doi: 10.14740/cr972. Epub 2020 Jan 26.

DOI:10.14740/cr972
PMID:32095193
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7011925/
Abstract

BACKGROUND

Atrial fibrillation (AF) is a hypercoagulable state. However, the intimate mechanisms leading to impaired coagulation and the timing of their activation are unclear. The aim of the study was to investigate the factors that initiate the coagulation cascade in the early hours (up to 48 h) of clinical manifestation of paroxysmal atrial fibrillation (PAF).

METHODS

Tissue factor (TF) level, coagulation activity of factor VII (FVIIa), factor XII (FXIIa) and factor XI (FXIa) were measured in plasma of 51 non-anticoagulated patients (26 men and 25 women, aged 59.84 ± 11.42 years) and 52 controls (26 men and 26 women, aged 59.50 ± 10.53 years) by enzyme-linked immunoassays and kinetic assays.

RESULTS

TF was higher in the PAF group (268.63 ± 90.62 pg/mL vs. 170.21 ± 66.19 pg/mL, P < 0.001) as well as FVIIa (170.82±59.39% vs. 95.17±37.90%, P < 0.001), FXIIa (218.31±84.04% vs. 148.41±53.94%, P < 0.001) and FXIa (178.41±55.94% vs. 111.75±37.33%, P < 0.001). Regression analysis showed that in the first 6 h of the disease, increase in time led to increase in FXIIa (r = 0.25, P < 0.05), FXIa (r = 0.75, P < 0.05), TF level (r = 0.25, P < 0.05) and FVIIa (r = 0.25, P < 0.05).

CONCLUSION

Hemocoagulation changes were observed even < 6 h after the onset of the disease. They suggest that PAF has an early tendency for hypercoagulability, with the involvement of the intrinsic and extrinsic pathways of coagulation.

摘要

背景

心房颤动(AF)是一种高凝状态。然而,导致凝血功能受损的具体机制及其激活时间尚不清楚。本研究旨在探讨阵发性心房颤动(PAF)临床表现早期(至48小时)启动凝血级联反应的因素。

方法

采用酶联免疫分析法和动力学分析法,检测了51例未抗凝患者(26例男性和25例女性,年龄59.84±11.42岁)和52例对照者(26例男性和26例女性,年龄59.50±10.53岁)血浆中的组织因子(TF)水平、凝血因子VII(FVIIa)、凝血因子XII(FXIIa)和凝血因子XI(FXIa)的凝血活性。

结果

PAF组的TF水平(268.63±90.62 pg/mL vs. 170.21±66.19 pg/mL,P<0.001)、FVIIa(170.82±59.39% vs. 95.17±37.90%,P<0.001)、FXIIa(218.31±84.04% vs. 148.41±53.94%,P<0.001)和FXIa(178.41±55.94% vs.  111.75±37.33%,P<0.001)均高于对照组。回归分析显示,在疾病发生的最初6小时内,时间延长导致FXIIa(r = 0.25,P<0.05)、FXIa(r = 0.75,P<0.05)、TF水平(r = 0.25,P<0.05)和FVIIa(r = 0.25,P<0.05)升高。

结论

在疾病发作后不到6小时就观察到血液凝固变化。这表明PAF早期有高凝倾向,涉及内源性和外源性凝血途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/eb59aecfb179/cr-11-022-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/4d50add5e910/cr-11-022-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/2b108d136d03/cr-11-022-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/4163e04aa1b8/cr-11-022-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/bb6fe519a3d7/cr-11-022-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/b9d89429c9e3/cr-11-022-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/ad6c390b0a18/cr-11-022-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/6c8bcefe1eae/cr-11-022-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/da414479a6c4/cr-11-022-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/eb59aecfb179/cr-11-022-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/4d50add5e910/cr-11-022-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/2b108d136d03/cr-11-022-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/4163e04aa1b8/cr-11-022-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/bb6fe519a3d7/cr-11-022-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/b9d89429c9e3/cr-11-022-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/ad6c390b0a18/cr-11-022-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/6c8bcefe1eae/cr-11-022-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/da414479a6c4/cr-11-022-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3401/7011925/eb59aecfb179/cr-11-022-g009.jpg

相似文献

1
Paroxysmal Atrial Fibrillation: Insight Into the Intimate Mechanisms of Coagulation.阵发性心房颤动:深入了解凝血的内在机制
Cardiol Res. 2020 Feb;11(1):22-32. doi: 10.14740/cr972. Epub 2020 Jan 26.
2
Paroxysmal atrial fibrillation: changes in factor VIII and von Willebrand factor impose early hypercoagulability.阵发性心房颤动:因子VIII和血管性血友病因子的变化导致早期高凝状态。
Arch Med Sci Atheroscler Dis. 2020 Jul 11;5:e140-e147. doi: 10.5114/amsad.2020.97101. eCollection 2020.
3
Paroxysmal Atrial Fibrillation: An Independent Risk Factor for Prothrombotic Conditions.阵发性心房颤动:血栓形成相关病症的独立危险因素。
J Atr Fibrillation. 2020 Aug 31;13(2):2297. doi: 10.4022/jafib.2297. eCollection 2020 Aug.
4
Paroxysmal atrial fibrillation is associated with early coagulation activity regardless of risk factors for embolism.阵发性心房颤动与早期凝血活性有关,与栓塞的危险因素无关。
Minerva Cardiol Angiol. 2021 Jun;69(3):269-276. doi: 10.23736/S2724-5683.20.05209-3. Epub 2020 Jul 10.
5
Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations?心房颤动与高凝状态:取决于临床因素还是/及基因改变?
J Thromb Thrombolysis. 2003 Dec;16(3):155-61. doi: 10.1023/B:THRO.0000024053.45693.fc.
6
Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke.活化的凝血因子IX、凝血因子XI和组织因子可识别接受华法林治疗的永久性心房颤动患者中存在缺血性中风风险的患者。
Arch Med Sci. 2016 Oct 1;12(5):1000-1007. doi: 10.5114/aoms.2015.54791. Epub 2015 Nov 17.
7
Early Changes in the Antithrombin and Thrombin-Antithrombin Complex in Patients With Paroxysmal Atrial Fibrillation.阵发性心房颤动患者抗凝血酶及凝血酶-抗凝血酶复合物的早期变化
Cardiol Res. 2016 Jun;7(3):89-94. doi: 10.14740/cr469w. Epub 2016 Jun 24.
8
Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation.心房颤动以时间依赖的方式激活血小板和凝血:一项对阵发性心房颤动患者的研究。
J Am Coll Cardiol. 1997 Jan;29(1):106-12. doi: 10.1016/s0735-1097(96)00427-5.
9
Effect of atrial fibrillation on the fibrino-coagulation system--study in patients with paroxysmal atrial fibrillation.心房颤动对纤维蛋白凝血病系统的影响——阵发性心房颤动患者的研究
Jpn Circ J. 1994 Nov;58(11):821-6. doi: 10.1253/jcj.58.821.
10
Rhythm-independent feature of heart rate dynamics common to atrial fibrillation and sinus rhythm in patients with paroxysmal atrial fibrillation.阵发性心房颤动患者心房颤动和窦性心律中心率动力学的节律无关特征
J Cardiol. 2003 Dec;42(6):269-76.

引用本文的文献

1
Vascular Endothelial Dysfunction and Immunothrombosis in the Pathogenesis of Atrial Fibrillation.血管内皮功能障碍与免疫血栓形成在心房颤动发病机制中的作用
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241296138. doi: 10.1177/10760296241296138.
2
Characterization of Biomarkers of Thrombo-Inflammation in Patients with First-Diagnosed Atrial Fibrillation.首次诊断为心房颤动患者的血栓炎症生物标志物特征。
Int J Mol Sci. 2024 Apr 8;25(7):4109. doi: 10.3390/ijms25074109.
3
Oral anticoagulant therapy for patients with new-onset atrial fibrillation following acute myocardial infarction: A narrative review.

本文引用的文献

1
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.抗栓治疗心房颤动:CHEST 指南和专家报告。
Chest. 2018 Nov;154(5):1121-1201. doi: 10.1016/j.chest.2018.07.040. Epub 2018 Aug 22.
2
Cardioverting acute atrial fibrillation and the risk of thromboembolism: not all patients are created equal .转复急性心房颤动与血栓栓塞风险:并非所有患者都一样。
Clin Med (Lond). 2017 Oct;17(5):419-423. doi: 10.7861/clinmedicine.17-5-419.
3
Should We Replace the Terms Intrinsic and Extrinsic Coagulation Pathways With Tissue Factor Pathway?
急性心肌梗死后新发房颤患者的口服抗凝治疗:一项叙述性综述。
Front Cardiovasc Med. 2022 Nov 3;9:1046298. doi: 10.3389/fcvm.2022.1046298. eCollection 2022.
4
Beneficial Effect of Edoxaban on Preventing Atrial Fibrillation and Coagulation by Reducing Inflammation HBG1/HBD Biomarkers.依度沙班通过降低炎症HBG1/HBD生物标志物预防心房颤动和凝血的有益作用。
Front Pharmacol. 2022 Jun 3;13:904317. doi: 10.3389/fphar.2022.904317. eCollection 2022.
Clin Appl Thromb Hemost. 2017 Nov;23(8):922-927. doi: 10.1177/1076029616673733. Epub 2016 Oct 18.
4
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动管理指南。
Eur J Cardiothorac Surg. 2016 Nov;50(5):e1-e88. doi: 10.1093/ejcts/ezw313. Epub 2016 Sep 23.
5
Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes.非瓣膜性心房颤动患者的颅外系统栓塞事件:发生率、危险因素和结局。
Circulation. 2015 Sep 1;132(9):796-803. doi: 10.1161/CIRCULATIONAHA.114.013243. Epub 2015 Jul 29.
6
Association of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression.止血标志物与心房颤动的关联:一项荟萃分析和荟萃回归分析
PLoS One. 2015 Apr 17;10(4):e0124716. doi: 10.1371/journal.pone.0124716. eCollection 2015.
7
Thrombosis: a major contributor to global disease burden.血栓形成:全球疾病负担的主要促成因素。
Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2363-71. doi: 10.1161/ATVBAHA.114.304488.
8
Tissue factor encryption and decryption: facts and controversies.组织因子的加密与解密:事实与争议。
Thromb Res. 2012 May;129 Suppl 2(Suppl 2):S13-7. doi: 10.1016/j.thromres.2012.02.021. Epub 2012 Mar 6.
9
A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation.特发性孤立性心房颤动患者血液可溶性 P 选择素、纤维蛋白原和血管性血友病因子水平的研究。
Europace. 2011 Jan;13(1):31-6. doi: 10.1093/europace/euq346. Epub 2010 Sep 18.
10
The impact of acute atrial fibrillation on the prothrombotic state in patients with essential hypertension.急性心房颤动对原发性高血压患者血栓前状态的影响。
Clin Biochem. 2010 Oct;43(15):1212-5. doi: 10.1016/j.clinbiochem.2010.07.013. Epub 2010 Jul 23.